Why You Should Not Worry About Eli Lilly (LLY) and Company’s Foundayo Treatment Prospects

Eli Lilly and Company (NYSE:LLY) is one of the top S&P 500 stocks by index weight. On April 15, BMO Capital reiterated an Outperform rating on Eli Lilly and Company (NYSE:LLY) and a $1,300 price target. The bullishness underscores the research firm’s confidence that the company is facing manageable post-marketing study requirements for the Foundayo treatment.

Why You Should Not Worry About Eli Lilly (LLY) and Company’s Foundayo Treatment Prospects

Following the US Food and Drug Administration approval of Foundayo on April 1 for chronic weight management, Eli Lilly is required to conduct post-marketing studies. The studies are to evaluate serious risks, including liver injury and gastric issues associated with the drug. Eli Lilly is already conducting the Phase 3 ACHIEVE-4 trial of daily Foundayo in patients with type 2 diabetes who are obese.

BMO Capital does not expect the studies to have any meaningful impact on the drug’s competitive edge. In addition, the post-market studies requirements are not an underlying risk to Eli Lily’s program but reflect the FDA’s conservatism.

Foundayo is a small-molecule drug that is easier and faster to produce, expected to give Eli Lilly a step up in the supply chain. According to BMO, its manufacturing advantage could be influential in the highly competitive oral obesity market.

Eli Lilly and Company (NYSE:LLY) is a major global pharmaceutical manufacturer, pioneering scientific research to develop medicines for chronic health issues. It specializes in treatments for diabetes, obesity, immunology, oncology, and neuroscience. The company is famously known for producing blockbuster GLP-1 drugs, Mounjaro and Zepbound.

While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Defense Stocks That Will Skyrocket and Top 10 Utility Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.